Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312546 · ClinicalTrials.gov registry record · Phase 1
Study of Valproic Acid to Treat HIV Infected Adults
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00312546 is a Phase 1 study that was terminated before completion, run by University of North Carolina, Chapel Hill. The registered enrollment target is 14 participants.
The verdict
NCT00312546, a Phase 1 study, was terminated before completion, sponsored by University of North Carolina, Chapel Hill.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
A histone deacetylase (HDAC) inhibitor is a class of drug that interferes with the function of HDAC, an enzyme that hides HIV within inactive CD4 cells. These drugs are normally used to treat seizures and other nervous system problems but have been found to work against HIV. The purpose of this study is to investigate the efficacy of valproic acid (VPA), an HDAC inhibitor, in treating HIV infected adults using anti-HIV drugs.
Interventions
- DRUG Enfuvirtide
- DRUG Valproic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00312546
The ClinicalTrials.gov registry entry for NCT00312546 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enfuvirtide is the first listed.
NCT00312546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00312546 about?
NCT00312546 is a clinical study titled "Study of Valproic Acid to Treat HIV Infected Adults". A histone deacetylase (HDAC) inhibitor is a class of drug that interferes with the function of HDAC, an enzyme that hides HIV within inactive CD4 cells. These drugs are normally used to treat seizures and other nervous system problems but have been found to work against HIV. The purpose of this stud...
What is the current status of trial NCT00312546?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2006-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00312546?
The interventions under investigation include: Enfuvirtide (DRUG), Valproic acid (DRUG).
Who is sponsoring clinical trial NCT00312546?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.